Protein Design Labs
MSL-109 Phase I/II trial results indicate the anti-cytomegalovirus antibody in combination with ganciclovir or foscarnet may delay progression to CMV retinitis at least twice as long as either drug alone. The data on 17 AIDS patients, presented June 10 at the Ninth International Conference on AIDS in Berlin, show that median delay in progression to CMV retinitis was 202 days compared to 60-100 days for ganciclovir or foscarnet in other studies. Protein Design Labs is planning to begin a Phase II/III trial of MSL-109 in CMV retinitis next year.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth